Fluoroquinolone-Associated Disability
Fluoroquinolone-associated disability FQAD is a severe, disabling, multisystem syndrome associated with fluoroquinolone exposure. The serious, persistent effects it encompasses have been documented in the medical literature for more than three decades and recognized through regulatory review for more than a decade.
Isn't it time patients are recognized?
Johanna Ihli, BSN — former ER/trauma/critical care RN · independent researcher, DIMD Initiative
Regulatory recognition: FDA and European regulators recognize that fluoroquinolones can cause disabling, long-lasting, and potentially permanent adverse effects involving multiple body systems. In 2026, France's Haute Autorité de Santé also initiated formal work on clinical guidance for managing serious fluoroquinolone adverse effects.
From Safety Signals to Mechanism: Mitochondrial dysfunction, oxidative stress, impaired cellular energy metabolism, and mitochondrial DNA injury have emerged as recurring findings across the fluoroquinolone literature. What were once recognized primarily as clinical safety signals are now being tied to measurable biological disruption. The accumulating evidence demonstrates that fluoroquinolone injury can directly disrupt mitochondrial function and the cellular systems responsible for energy production, repair, and recovery.
Experimental mechanisms: Laboratory studies demonstrate that fluoroquinolones can disrupt mitochondrial DNA topology and replication, increase oxidative stress, impair mitochondrial function, interfere with GABA-A receptor signaling, and disturb tendon extracellular-matrix biology.
Confirmed human-cell off-targets: Chemical proteomics has identified AIFM1 and IDH2 as direct fluoroquinolone off-targets in human-cell systems, with downstream effects involving mitochondrial Complexes I and IV.
Clinical documentation exists: Fluoroquinolone-specific ICD-10-CM adverse-effect codes now allow these reactions and their sequelae to be documented longitudinally.
Population burden: The true incidence, prevalence, long-term disability burden, and recovery rate remain unknown because no dedicated longitudinal surveillance system exists.
Individual susceptibility: We do not yet know why similar exposures produce no apparent injury in some patients and profound multisystem disability in others.
Pathway interaction: The relative contributions and interactions of mitochondrial injury, neurological injury, extracellular-matrix disruption, connective-tissue injury, and other pathways remain incompletely defined in human FQAD.
Clinical identification: Validated biomarkers, broadly accepted diagnostic criteria, and reliable methods for identifying reduced bioenergetic reserve are still lacking.
Natural history: Relapse, recovery, delayed progression, re-exposure risk, and the proposed reduced-reserve or second-hit model require prospective human study.
Treatment: No established evidence-based treatment pathway currently exists for persistent multisystem fluoroquinolone injury.
Patient burden: The true burden of FQAD remains unmeasured. Its physical, emotional, functional, and financial consequences are substantial, yet no dedicated system tracks disability, healthcare utilization, lost income, caregiving burden, or long-term psychosocial impact.
The Harm Is Recognized. The Population Is Not Yet Measured.
A syndrome of delayed, persistent, and potentially disabling adverse effects involving tendons, muscles, joints, peripheral nerves, and the central nervous system following exposure to fluoroquinolone antibiotics.
FQAD is not a patient-invented diagnosis. The FDA itself named Fluoroquinolone-Associated Disability (FQAD) and defined it for its own pharmacovigilance case review, requiring: substantial disability or disruption of normal life functions; adverse events involving two or more body systems; and adverse effects lasting at least 30 days after fluoroquinolone discontinuation. These were FDA's own pharmacovigilance case-review criteria, not a formal clinical diagnostic definition — formal clinical classification and diagnostic criteria for FQAD have since been published by Stefan Pieper.
What distinguishes FQAD from other drug adverse effects is its multisystem nature, delayed onset, and persistence long after the antibiotic has cleared the body. Symptoms may emerge or worsen after the course is finished, and disabling effects can persist for months or years.
"The drug is gone. The injury may not be."
Fluoroquinolones are among the most widely prescribed antibiotic classes in the world. Ciprofloxacin, levofloxacin, and moxifloxacin are routinely used for urinary tract infections, respiratory infections, and a broad range of indications — often in patients who were previously healthy and had no warning that a standard course of antibiotics could produce lasting disability.
Key Regulatory Milestones
FDA Boxed Warning — Tendinopathy & Rupture
FDA adds black box warning to all systemic fluoroquinolones for risk of tendinitis and tendon rupture, including risk persisting after discontinuation.
FDA Warning — Peripheral Neuropathy
FDA updates labeling to warn that peripheral neuropathy may occur "soon after" initiation and may be permanent — a landmark acknowledgment of irreversibility.
FDA Safety Communication — Disabling & Potentially Permanent Effects
FDA issues Drug Safety Communication explicitly describing "disabling and potentially permanent serious side effects" involving tendons, muscles, joints, nerves, and the CNS. Recommends restricting use for minor infections. First use of the word permanent in this context.
EMA Restriction — Disabling Musculoskeletal & Nervous System Effects
European Medicines Agency recommends restrictions on fluoroquinolone use, citing disabling and long-lasting adverse reactions affecting the musculoskeletal system and nervous system.
FDA Citizen Petition — Enhanced Informed Consent
Docket FDA-2026-P-5116 accepted for filing. Requests stronger informed-consent language and improved patient-facing risk communication to reflect what the regulatory record already documents.
Two Parallel Stories — One Widening Gap
Mitochondrial science advanced dramatically from the 1960s onward — confirming mechanisms, mapping pathways, and accumulating evidence of drug-induced energy system injury. Fluoroquinolone safety frameworks moved far more slowly. The gap between what biology knew and what regulation reflected is the structural problem this initiative exists to close. Click any science milestone to expand the mechanistic detail.
What Human Studies Show
The regulatory record above reflects decades of accumulating clinical signal. More recent population-scale research adds a concrete, quantified picture of post-exposure neurological risk and its timing.
The Multisystem Phenotype — and Why It Gets Misattributed
Because FQAD crosses organ systems and follows a delayed onset pattern, it is routinely fragmented into separate specialty diagnoses. Each specialist sees their piece of the picture — the neurologist sees neuropathy, the rheumatologist sees connective tissue dysfunction, the cardiologist sees dysautonomia — without a framework that unifies them. The following table maps common diagnostic categories to their underlying mitochondrial mechanisms within the FQAD framework.
One patient. Different specialists. Different labels.
Select a diagnosis below to see how it connects back to a single underlying pattern.
Swipe to explore diagnoses →
| Common Misdiagnosis | Typical Presentation in FQAD | Underlying Mitochondrial Mechanism |
|---|---|---|
| Fibromyalgia-like syndrome | Widespread musculoskeletal pain, fatigue, tender points, sleep disruption | Bioenergetic dysfunction, oxidatFive stress, mitochondrial quality control impairment |
| ME/CFS-like syndrome | Post-exertional malaise, profound fatigue disproportionate to activity, cognitive dysfunction | Impaired ATP reserve, ROS amplification, failure of bioenergetic threshold under exertion |
| Peripheral neuropathy | Burning, tingling, numbness in extremities; electric shock sensations; sensory loss | Neuronal mitochondrial vulnerability; high energy demand of peripheral axons; Complex I/IV impairment |
| Dysautonomia / POTS-like syndrome | Heart rate instability, orthostatic intolerance, blood pressure dysregulation, temperature dysregulation | Autonomic nervous system bioenergetic failure; impaired mitochondrial function in autonomic neurons |
| Cognitive dysfunction syndrome | Brain fog, memory impairment, word-finding difficulty, impaired processing speed | Neuronal calcium dysregulation, ROS-mediated synaptic dysfunction, CNS bioenergetic deficit |
| Connective tissue / musculoskeletal disorder | Tendon pain and rupture, joint hypermobility, muscle weakness, recurrent injury | Oxidative damage to collagen-producing cells; impaired tissue repair via mitochondrial ROS; TOP2β-mediated mtDNA damage in tenocytes |
| Anxiety / psychiatric disorder | New-onset anxiety, panic attacks, depersonalization, emotional dysregulation | Reduced GABAergic inhibition can increase neuronal excitability, while mitochondrial dysfunction and oxidative stress may further destabilize CNS function. |
| Idiopathic multisystem illness | Symptoms spanning multiple systems with no unifying diagnosis; labeled functional or psychosomatic | Systemic bioenergetic failure — the unified mechanism that organ-based frameworks cannot see as a single entity |
A Short Exposure, a Long Aftermath
How can a short exposure cause problems that appear or worsen after the drug is gone?
This five-step model proposes one possible mitochondrial explanation.
The Proposed Five-Step Mechanism
This is a hypothesis-generating model grounded in converging biological evidence, not a fully validated clinical mechanism. It proposes a plausible pathway from a short fluoroquinolone exposure to delayed, self-sustaining mitochondrial injury.
What We Know — and What We Still Need to Prove
Fluoroquinolones can disrupt mitochondrial biology through multiple experimentally documented pathways.
The mechanism that could allow this dysfunction to become self-sustaining and progressive after drug clearance remains a hypothesis requiring direct human testing.
Newer Evidence: Neural and Tendon-Level Injury
Two 2026 studies extend the multi-hit picture introduced in Step 2 above — one confirming mitochondrial disruption directly in human neural tissue, the other identifying a parallel, non-mitochondrial injury pathway in tendon cells. Together they broaden what "multi-hit" means in FQAD: not just multiple mitochondrial targets, but potentially multiple, partly independent injury systems.
When a Primed System Meets Another Exposure
The reduced-reserve and second-hit model below is a proposed explanatory framework grounded in mitochondrial population dynamics — not a mechanism directly validated in human longitudinal studies. It is offered as a plausible explanation for a recurring clinical pattern, and is one of the open questions listed later on this page.
One of the most clinically important — and least recognized — aspects of FQAD is what happens when a patient with prior fluoroquinolone exposure receives a second course. Or a different mitochondria-impairing medication. Or undergoes significant physiological stress.
In a mitochondrially primed system — one where MQC capacity has already been depleted, heteroplasmy has already shifted, and bioenergetic reserve is already reduced — a subsequent insult does not produce a proportional response. It can produce a disproportionate, catastrophic escalation.
This is the "second-hit" phenomenon. Patients who tolerated a first fluoroquinolone course with manageable effects sometimes describe the second course as the one that changed everything — a sudden, dramatic worsening from which they did not recover.
This pattern is not coincidence, and it is not psychological sensitization. It is an expected outcome of mitochondrial population dynamics in a system that has already crossed a critical threshold.
Currently, no prescribing system flags prior fluoroquinolone adverse effects when a new prescription is written. No electronic health record alerts a clinician that this patient has a history suggestive of FQAD before a second course is initiated. This is the gap the FQAD framework and the FDA petition exist to address.
Drug clears within days. Patient may notice fatigue, joint discomfort, or neurologic symptoms — often dismissed or attributed to the original infection. MQC systems are stressed but partially compensate. Bioenergetic reserve is reduced. Heteroplasmy begins to shift.
Months or years pass. Patient may be "functional" but operating with reduced bioenergetic reserve. Subclinical mitochondrial dysfunction is present but compensated — clinically silent, not detectable by standard workup. The system is primed.
A second fluoroquinolone course — or another mitochondria-impairing drug, or significant physiological stress — strikes a system with depleted reserve and no buffer. The result is a catastrophic escalation that can produce permanent, severe, multisystem disability. The second hit is not the cause. The primed system is.
Why FQAD Gets Missed
Symptoms May Appear After the Drug Is Stopped
If a clinician is only watching for reactions during treatment, a symptom that emerges weeks later is easy to miss as related.
More Than One Body System May Be Affected
A tendon specialist sees tendon pain. A neurologist sees neuropathy. Without a unifying framework, the pattern splits into separate, unconnected diagnoses.
A Person May Have Tolerated Fluoroquinolones Before
Prior uneventful exposure is often taken as reassurance that the drug is safe for that patient — when it may instead mean prior exposure quietly primed the system.
The Pharmacokinetic–Clinical Mismatch
Traditional adverse-event frameworks assume a fairly direct relationship between drug presence and drug effect: if a drug causes harm, the harm should appear while the drug is present, or shortly after.
But mitochondrial injury does not follow this model. The drug may leave the body long before the clinical problem is resolved. A drug's plasma half-life tells us almost nothing about the biological timeline of the injury it may have started at the cellular level.
This mismatch is not idiosyncratic or mysterious. If the propagation step described above (Step 4 of the five-step mechanism) is correct, it is an expected outcome of mitochondrial population dynamics under stress — the clinical trajectory becomes decoupled from the pharmacokinetic one.
This is why patients who report worsening symptoms months or years after a medication course are not being dramatic or confused about causality. They may be describing the correct biology.
This mismatch is also why delayed recognition happens, and why longer follow-up — not just short-window adverse-event reporting — matters for a condition like this one.
What We Still Do Not Know — Because It Has Not Been Measured
No reliable incidence, prevalence, or long-term disability estimates. Without dedicated longitudinal surveillance, the true population burden of FQAD is unknown.
No dedicated prospective natural-history cohort or longitudinal registry. Existing evidence is built from claims data, case reports, and pharmacovigilance signals — not a cohort followed forward specifically to observe FQAD's course.
No validated biomarker or broadly accepted diagnostic pathway. Clinicians currently have no reliable way to confirm reduced bioenergetic reserve or distinguish FQAD from its commonly misattributed look-alikes.
Incomplete understanding of susceptibility, recovery, relapse, progression, and re-exposure. Why some patients recover and others do not — and what determines the second-hit trajectory described above — remains an open question requiring prospective human study.
No established evidence-based treatment pathway. There is currently no validated, evidence-based approach to managing persistent multisystem fluoroquinolone injury.
These are gaps in measurement, not evidence that the harm is rare or resolved. A condition without a surveillance system will always look smaller than it is — because the system that would count it was never built. Closing that gap is the purpose of the registry and the FDA petition below.
Download the Clinician Education Packet
Three tiers, from a one-page leave-behind to full reference tables — built for the time you actually have.
ICD-10-CM Coding for Fluoroquinolone Adverse Effects
ICD-10-CM now includes fluoroquinolone-specific adverse-effect codes, creating a mechanism for clinicians to document these reactions in the medical record. Their usefulness depends entirely on clinician recognition of the exposure-effect relationship.
When fluoroquinolone toxicity is not considered, it is not coded. When it is not coded, it is not counted, followed, or incorporated into the longitudinal safety record.
Coding sequence matters: when a fluoroquinolone was correctly prescribed and properly administered, the clinical manifestation or condition caused by the adverse effect should generally be coded first, followed by the appropriate fluoroquinolone adverse-effect code.
For clinicians: Proper coding supports both individual patient care and population-level pharmacovigilance. Documenting a clinically supported relationship between prior fluoroquinolone exposure and the patient’s adverse effects is accurate clinical documentation. It is not an assignment of legal blame.
Adverse Effect of Fluoroquinolone Antibiotics — Initial Encounter
Use during active treatment of an adverse effect caused by a properly prescribed and administered fluoroquinolone. “Initial encounter” refers to the active-treatment phase, not simply the patient’s first visit.
Adverse Effect of Fluoroquinolone Antibiotics — Subsequent Encounter
Use during routine follow-up, recovery, rehabilitation, or continued management after the active-treatment phase of the adverse effect.
Adverse Effect of Fluoroquinolone Antibiotics — Sequela
Use when documenting a residual, persistent, or late effect remaining after the acute adverse-reaction phase. The residual clinical condition is coded first, followed by T36.AX5S.
The Evidence Exists. The Framework Exists. Now We Build the Record.
Every patient who submits a registry record, every clinician who codes correctly, every policymaker who reads the petition — that is how the evidence base grows.